Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works

Mild Cognitive Impairment: Clinical Characterization and Outcome

Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980 · see citing works

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease

Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · see citing works

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · see citing works

Amyloid deposition as the central event in the aetiology of Alzheimer’s disease

Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · see citing works

Revising the definition of Alzheimer's disease: a new lexicon

Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · see citing works

Telephone Interview for Cognitive Status

Brandt, J., Spencer, M., & Folstein, M. F. (1988) · PsycTESTS Dataset · doi:10.1037/t28542-000 · Cited by 1,504 · see citing works

CSF markers for incipient Alzheimer's disease

Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · see citing works

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment

Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176 · see citing works

Frequent amyloid deposition without significant cognitive impairment among the elderly

Aizenstein, H. J., Nebes, R. D., Saxton, J. A., Price, J. C., Mathis, C. A., Tsopelas, N. D., Ziolko, S. K., James, J. A., Snitz, B. E., Houck, P. R., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.1509 · Cited by 1,059 · see citing works

Cerebrospinal Fluid tau/β-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults

Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · see citing works

Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease

Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22248 · Cited by 833 · see citing works

The amyloid hypothesis for Alzheimer’s disease: A critical reappraisal

Hardy, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06181.x · Cited by 814 · see citing works

-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease

Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., Mathis, C. A., Klunk, W. E., Masters, C. L., & Rowe, C. C. (2007) · Brain · doi:10.1093/brain/awm238 · Cited by 789 · see citing works

Improved discrimination of AD patients using β-amyloid _(1-42) and tau levels in CSF

Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724 · see citing works

Prediction of Dementia by Subjective Memory Impairment Effects of Severity and Temporal Association With Cognitive Impairment Dementia and Subjective Memory Impairment

Jessen, F. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.30 · Cited by 681 · see citing works

Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship

Nelson, P. T., Braak, H., & Markesbery, W. R. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181919a48 · Cited by 643 · see citing works

Neuropathologic Features of Amnestic Mild Cognitive Impairment

Petersen, R. C., Parisi, J. E., Dickson, D. W., Johnson, K. A., Knopman, D. S., Boeve, B. F., Jicha, G. A., Ivnik, R. J., Smith, G. E., Tangalos, E. G., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.665 · Cited by 616 · see citing works

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study

Visser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L.-O., Freund-Levi, Y., Tsolaki, M., Minthon, L., Wallin, Å. K., Hampel, H., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70139-5 · Cited by 614 · see citing works

Cerebral amyloid deposition and diffuse plaques in ``normal'' aging: Evidence for presymptomatic and very mild Alzheimer's disease

Morris, J. C., Storandt, M., McKeel, D. W., Rubin, E. H., Price, J. L., Grant, E. A., & Berg, L. (1996) · Neurology · doi:10.1212/wnl.46.3.707 · Cited by 603 · see citing works

Association Between Memory Complaints and Incident Alzheimer’s Disease in Elderly People With Normal Baseline Cognition

Geerlings, M. I., Jonker, C., Bouter, L. M., Adèr, H. J., & Schmand, B. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.4.531 · Cited by 487 · see citing works

Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease

Morris, J. C., Roe, C. M., Grant, E. A., Head, D., Storandt, M., Goate, A. M., Fagan, A. M., Holtzman, D. M., & Mintun, M. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.269 · Cited by 476 · see citing works

MRI and CSF biomarkers in normal, MCI, and AD subjects

Vemuri, P., Wiste, H. J., Weigand, S. D., Shaw, L. M. J., Trojanowski, J. Q., Weiner, M. W., Knopman, D. S., Petersen, R. C., & Jack, C. R. (2009) · Neurology · doi:10.1212/wnl.0b013e3181af79fb · Cited by 398 · see citing works

Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift

Golde, T. E., Schneider, L. S., & Koo, E. H. (2011) · Neuron · doi:10.1016/j.neuron.2011.01.002 · Cited by 382 · see citing works

Amyloid-β(1–42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease

Mulder, C., Verwey, N. A., van der Flier, W. M., Bouwman, F. H., Kok, A., van Elk, E. J., Scheltens, P., & Blankenstein, M. A. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.130518 · Cited by 332 · see citing works

CSF tau/Aβ 42 ratio for increased risk of mild cognitive impairment

Li, G., Sokal, I., Quinn, J. F., Leverenz, J. B., Brodey, M., Schellenberg, G. D., Kaye, J. A., Raskind, M. A., Zhang, J., Peskind, E. R., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000267428.62582.aa · Cited by 274 · see citing works

Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease

Knopman, D. S., Jack, C. R., Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Ivnik, R. J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182563bbe · Cited by 243 · see citing works

Cerebrospinal fluid -amyloid 1-42 concentration may predict cognitive decline in older women

Gustafson, D. R., Skoog, I., Rosengren, L., Zetterberg, H., & Blennow, K. (2006) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.100529 · Cited by 214 · see citing works

Cerebrospinal Fluid Tau and β-Amyloid 42 Proteins Identify Alzheimer Disease in Subjects With Mild Cognitive Impairment

Riemenschneider, M. J., Lautenschlager, N. T., Wagenpfeil, S., Diehl, J., Drzezga, A. E., & Kurz, A. (2002) · Archives of Neurology · doi:10.1001/archneur.59.11.1729 · Cited by 212 · see citing works

Multicenter clinicopathological correlation in dementia

Victoroff, J., Mack, W. J., Lyness, S. A., & Chui, H. C. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.10.1476 · Cited by 185 · see citing works

Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature

Diniz, B. S., Pinto, J. A., & Forlenza, O. V. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701535502 · Cited by 168 · see citing works

Cerebrospinal Fluid Biomarkers Predict Decline in Subjective Cognitive Function over 3 Years in Healthy Elderly

Stomrud, E., Hansson, O., Blennow, K., Minthon, L., & Londos, E. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000105017 · Cited by 164 · see citing works

CSF biomarkers predict rate of cognitive decline in Alzheimer disease

Kester, M. I., van der Vlies, A. E., Blankenstein, M. A., Pijnenburg, Y. A. L., van Elk, E. J., Scheltens, P., & van der Flier, W. M. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bd8271 · Cited by 158 · see citing works

Biomarkers as Predictors for Conversion from Mild Cognitive Impairment to Alzheimer-Type Dementia: Implications for Trial Design

van Rossum, I. A., Vos, S. J. B., Handels, R. L. H., & Visser, P. J. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091606 · Cited by 143 · see citing works

Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI

Ewers, M., Büerger, K., Teipel, S. J., Scheltens, P., Schröder, J., Zinkowski, R. P., Bouwman, F. H., Schönknecht, P., Schoonenboom, N. S. M., Andreasen, N. C., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000286944.22262.ff · Cited by 142 · see citing works

CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies

Mitchell, A. J. (2009) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.167791 · Cited by 123 · see citing works

Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β(1-42) , Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop

Teunissen, C. E., Verwey, N. A., Kester, M. I., van Uffelen, K. W. J., & Blankenstein, M. A. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/635053 · Cited by 70 · see citing works

CSF Biomarkers in Alzheimer's Disease and Controls: Associations with APOE Genotype are Modified by Age

Kester, M. I., Blankenstein, M. A., Bouwman, F. H., van Elk, E. J., Scheltens, P., & van der Flier, W. M. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0999 · Cited by 50 · see citing works

Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease

Roe, C. M., Fagan, A. M., Williams, M., Ghoshal, N., Aeschleman, M., Grant, E., Marcus, D. S., Mintun, M. A., Holtzman, D. M., & Morris, J. C. (2011) · Neurology · doi:10.1212/wnl.0b013e31820af900 · Cited by 49 · see citing works

Cognitive Profiles of Incipient Dementia in the Goteborg MCI Study

Nordlund, A., Rolstad, S., Göthlin, M., Edman, Å., Hansen, S., & Wallin, A. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000321352 · Cited by 47 · see citing works

¹¹C-PIB PET in subjective cognitive impairment

Rodda, J., Okello, A., Edison, P., Dannhauser, T., Brooks, D. J., & Walker, Z. (2010) · European Psychiatry · doi:10.1016/j.eurpsy.2009.07.011 · Cited by 36 · see citing works

Telefonisch Interview Cognitieve Status (TICS): psychometrische aspecten

Kempen, G. I. J. M., Meier, A. J. L., Bouwens, S., van Deursen, J. A., & Verhey, F. R. J. (2007) · Tijdschrift voor Gerontologie en Geriatrie · doi:10.1007/bf03074823 · Cited by 22 · see citing works

NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease

Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537 · see citing works

Alzheimer’s Disease

Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125 · see citing works

A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease

Jessen, F., Amariglio, R. E., van Boxtel, M., Breteler, M., Ceccaldi, M., Chételat, G., Dubois, B., Dufouil, C., Ellis, K. A., van der Flier, W. M., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.01.001 · Cited by 3,014 · see citing works

Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria

Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925 · see citing works

Alzheimer's disease

Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853 · see citing works

Defeating Alzheimer's disease and other dementias: a priority for European science and society

Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676 · see citing works

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis

Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610 · see citing works

Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis

Mitchell, A. J., Beaumont, H., Ferguson, D. Y., Yadegarfar, M., & Stubbs, B. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12336 · Cited by 1,171 · see citing works

Subjective Cognitive Decline in Preclinical Alzheimer's Disease

Rabin, L. A., Smart, C. M., & Amariglio, R. E. (2017) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032816-045136 · Cited by 590 · see citing works

Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies

Rabin, L. A., Initiative, T. A. D. N., Smart, C. M., Crane, P. K., Amariglio, R. E., Berman, L., Boada, M., Buckley, R. F., Chételat, G., Dubois, B., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150154 · Cited by 472 · see citing works

Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia

Slot, R. E. R., Sikkes, S. A. M., Berkhof, J., Brodaty, H., Buckley, R., Cavedo, E., Dardiotis, E., Guillo‐Benarous, F., Hampel, H., Kochan, N. A., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.10.003 · Cited by 428 · see citing works

Amsterdam Dementia Cohort: Performing Research to Optimize Care

van der Flier, W. M., & Scheltens, P. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170850 · Cited by 379 · see citing works

Orexinergic System Dysregulation, Sleep Impairment, and Cognitive Decline in Alzheimer Disease

Liguori, C., Romigi, A., Nuccetelli, M., Zannino, S., Sancesario, G., Martorana, A., Albanese, M., Mercuri, N. B., Izzi, F., Bernardini, S., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2510 · Cited by 355 · see citing works

Plasma Amyloid as Prescreener for the Earliest <scp>A</scp> lzheimer Pathological Changes

Verberk, I. M. W., Slot, R. E., Verfaillie, S. C. J., Heijst, H., Prins, N. D., van Berckel, B. N. M., Scheltens, P., Teunissen, C. E., & van der Flier, W. M. (2018) · Annals of Neurology · doi:10.1002/ana.25334 · Cited by 315 · see citing works

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry

Lewczuk, P., Riederer, P. F., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramı́rez, A., Parnetti, L., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 308 · see citing works

From Subjective Cognitive Complaints to Dementia

Mendonça, M., Alves, L., & Bugalho, P. (2015) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317515592331 · Cited by 278 · see citing works

Functional cognitive disorders: a systematic review

McWhirter, L., Ritchie, C., Stone, J., & Carson, A. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30405-5 · Cited by 240 · see citing works

Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE)

Jessen, F., Spottke, A. E., Boecker, H., Brosseron, F., Büerger, K., Catak, C., Fließbach, K., Franke, C., Fuentes, M., Heneka, M. T., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0314-2 · Cited by 233 · see citing works

Subjective Cognitive Concerns and Neuropsychiatric Predictors of Progression to the Early Clinical Stages of Alzheimer Disease

Donovan, N. J., Amariglio, R. E., Zoller, A. S., Rudel, R. K., Gómez‐Isla, T., Blacker, D., Hyman, B. T., Locascio, J. J., Johnson, K. A., Sperling, R. A., et al. (2014) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2014.02.007 · Cited by 228 · see citing works

Obstructive Sleep Apnea is Associated With Early but Possibly Modifiable Alzheimer’s Disease Biomarkers Changes

Liguori, C., Mercuri, N. B., Izzi, F., Romigi, A., Cordella, A., Sancesario, G., & Placidi, F. (2017) · SLEEP · doi:10.1093/sleep/zsx011 · Cited by 215 · see citing works

Fluid biomarkers in Alzheimer’s disease – current concepts

Rosén, C., Hansson, O., Blennow, K., & Zetterberg, H. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-20 · Cited by 214 · see citing works

CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)

Ritchie, C. W., Smailagic, N., Noel-Storr, A. H., Ukoumunne, O. C., Ladds, E. C., & Martin, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010803.pub2 · Cited by 208 · see citing works

Subjective and objective cognitive decline at the pre-dementia stage of Alzheimer’s disease

Jessen, F. (2014) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0539-z · Cited by 196 · see citing works

Prevalence and risk of progression of preclinical Alzheimer’s disease stages: a systematic review and meta-analysis

Parnetti, L., Chipi, E., Salvadori, N., D’Andrea, K., & Eusebi, P. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0459-7 · Cited by 194 · see citing works

ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project

Ebenau, J. L., Timmers, T., Wesselman, L. M. P., Verberk, I. M. W., Verfaillie, S. C. J., Slot, R. E. R., van Harten, A. C., Teunissen, C. E., Barkhof, F., van den Bosch, K. A., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009724 · Cited by 191 · see citing works

Self-reported memory complaints

Kryscio, R. J., Abner, E. L., Cooper, G. E., Fardo, D. W., Jicha, G. A., Nelson, P. T., Smith, C. D., Eldik, L. J. V., Wan, L., & Schmitt, F. A. (2014) · Neurology · doi:10.1212/wnl.0000000000000856 · Cited by 189 · see citing works

Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology

Hampel, H. J., (APMI), F. T. A. P. M. I., Toschi, N., Babiloni, C., Baldacci, F., Black, K. L., Bokde, A. L. W., Bun, R. S., Cacciola, F., Cavedo, E., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179932 · Cited by 181 · see citing works

Gray matter atrophy pattern in elderly with subjective memory impairment

Peter, J., Scheef, L., Abdulkadir, A., Boecker, H., Heneka, M., Wagner, M., Koppara, A., Klöppel, S., Jessen, F., & Initiative, A. D. N. (2014) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2013.05.1764 · Cited by 165 · see citing works

Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer’s Disease: Potential and Limitations

Cosín‐Tomás, M., Antonell, A., Lladó, A., Alcolea, D. A., Fortea, J., Ezquerra, M., Lleó, A., Martı́, M. J., Pallàs, M., Sánchez‐Valle, R., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0088-8 · Cited by 157 · see citing works

Subjective cognitive decline: The first clinical manifestation of Alzheimer's disease?

Studart‐Neto, A., & Nitríni, R. (2016) · Dementia & Neuropsychologia · doi:10.1590/s1980-5764-2016dn1003002 · Cited by 156 · see citing works

EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects

Gouw, A. A., Alsema, A. M., Tijms, B. M., Borta, A., Scheltens, P., Stam, C. J., & van der Flier, W. M. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.05.017 · Cited by 147 · see citing works

Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort

de Wilde, A., van der Flier, W. M., Pelkmans, W., Bouwman, F. H., Verwer, J. H., Groot, C., van Buchem, M. M., Zwan, M. D., Ossenkoppele, R., Yaqub, M. M., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1346 · Cited by 151 · see citing works

From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution.

Cheng, Y.-W., Chen, T.-F., & Chiu, M.-J. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s123428 · Cited by 150 · see citing works

Preclinical AD predicts decline in memory and executive functions in subjective complaints

van Harten, A. C., Smits, L. L., Teunissen, C. E., Visser, P. J., Koene, T., Blankenstein, M. A., Scheltens, P., & van der Flier, W. M. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a8418b · Cited by 143 · see citing works

Cerebrospinal Fluid Level of YKL-40 Protein in Preclinical and Prodromal Alzheimer's Disease

Antonell, A., Mansilla, A., Rami, L., Lladó, A., Iranzo, Á., Olives, J., Balasa, M., Sánchez‐Valle, R., & Molinuevo, J. L. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140624 · Cited by 137 · see citing works

Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects

Toledo, J. B., Zetterberg, H., van Harten, A. C., Glodzik, L., Martinez-Lage, P., Bocchio-Chiavetto, L., Rami, L., Hansson, O., Sperling, R., Engelborghs, S., et al. (2015) · Brain · doi:10.1093/brain/awv199 · Cited by 136 · see citing works

Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results

Slot, R. E. R., Verfaillie, S. C. J., Overbeek, J. M., Timmers, T., Wesselman, L. M. P., Teunissen, C. E., Dols, A., Bouwman, F. H., Prins, N. D., Barkhof, F., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0390-y · Cited by 132 · see citing works

Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study

van Maurik, I. S., Vos, S. J. B., Bos, I., Bouwman, F. H., Teunissen, C. E., Scheltens, P., Barkhof, F., Frölich, L., Kornhuber, J., Wiltfang, J., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30283-2 · Cited by 126 · see citing works

Autophagy in health and disease: From molecular mechanisms to therapeutic target

Lu, G. X., Wang, Y., Shi, Y. P., Zhang, Z., Huang, C., He, W., Wang, C., & Shen, H. (2022) · MedComm · doi:10.1002/mco2.150 · Cited by 127 · see citing works

Mindfulness training for older adults with subjective cognitive decline: Results from a pilot randomized controlled trial.

Smart, C. M., Segalowitz, S. J., Mulligan, B. P., Koudys, J., & Gawryluk, J. R. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150992 · Cited by 123 · see citing works

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review

Hansson, O., Mikulskis, A., Fagan, A. M., Teunissen, C. E., Zetterberg, H., Vanderstichele, H., Molinuevo, J. L., Shaw, L. M. J., Vandijck, M. L. J., Verbeek, M. M., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.05.008 · Cited by 122 · see citing works

Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment

Wolfsgruber, S., Polcher, A., Koppara, A., Kleineidam, L., Frölich, L., Peters, O., Hüll, M., Rüther, E., Wiltfang, J., Maier, W., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161252 · Cited by 114 · see citing works

Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia

Forlenza, O. V., Radanovic, M., Talib, L. L., Aprahamian, I., Diniz, B. S., Zetterberg, H., & Gattaz, W. F. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.09.003 · Cited by 110 · see citing works

Assessing brain plasticity across the lifespan with transcranial magnetic stimulation: why, how, and what is the ultimate goal?

Freitas, C., Farzan, F., & Pascual‐Leone, Á. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00042 · Cited by 109 · see citing works

Subjective Cognitive Decline and Related Cognitive Deficits

Si, T., Xing, G., & Han, Y. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00247 · Cited by 104 · see citing works

Memory self-awareness in the preclinical and prodromal stages of Alzheimer’s disease

Vannini, P., Amariglio, R. E., Hanseeuw, B. J., Johnson, K. A., McLaren, D. G., Chhatwal, J. P., Pascual‐Leone, Á., Rentz, D. M., & Sperling, R. A. (2017) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2017.04.002 · Cited by 100 · see citing works

Specific Features of Subjective Cognitive Decline Predict Faster Conversion to Mild Cognitive Impairment

Fernández-Blázquez, M. A., Ávila-Villanueva, M., Maestú, F., & Medina, M. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150956 · Cited by 98 · see citing works

Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease

Leuzy, A., Bollack, A., Pellegrino, D., Teunissen, C. E., Joie, R. L., Rabinovici, G. D., Franzmeier, N., Johnson, K. A., Barkhof, F., Shaw, L. M. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14528 · Cited by 97 · see citing works

Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer’s Biomarkers in Daily Practice (ABIDE) Project

van Maurik, I. S., Zwan, M. D., Tijms, B. M., Bouwman, F. H., Teunissen, C. E., Scheltens, P., Wattjes, M. P., Barkhof, F., Berkhof, J. H., van der Flier, W. M., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.2712 · Cited by 89 · see citing works

Apolipoproteins E and J interfere with amyloid‐beta uptake by primary human astrocytes and microglia in vitro

Mulder, S. D., Nielsen, H. M., Blankenstein, M. A., Eikelenboom, P., & Veerhuis, R. (2014) · Glia · doi:10.1002/glia.22619 · Cited by 84 · see citing works

Exercise-Related Changes of Networks in Aging and Mild Cognitive Impairment Brain

Huang, P., Fang, R., Li, B., & Chen, S. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00047 · Cited by 85 · see citing works

Sleep dysregulation, memory impairment, and CSF biomarkers during different levels of neurocognitive functioning in Alzheimer’s disease course

Liguori, C., Placidi, F., Izzi, F., Spanetta, M., Mercuri, N. B., & Pucchio, A. D. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0571-3 · Cited by 74 · see citing works

CSF Biomarkers in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease

Papaliagkas, V. T., Kalinderi, K., Vareltzis, P. K., Μoraitou, D., Papamitsou, T., & Chatzidimitriou, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108976 · Cited by 73 · see citing works

Biochemical and Neuroimaging Studies in Subjective Cognitive Decline: Progress and Perspectives

Sun, Y., Yang, F., Lin, C., & Han, Y. (2015) · CNS Neuroscience &amp; Therapeutics · doi:10.1111/cns.12395 · Cited by 71 · see citing works

Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline

Verfaillie, S. C. J., Tijms, B. M., Versteeg, A., Benedictus, M. R., Bouwman, F. H., Scheltens, P., Barkhof, F., Vrenken, H., & van der Flier, W. M. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.10.007 · Cited by 68 · see citing works

White matter degeneration in subjective cognitive decline: a diffusion tensor imaging study

Li, X.-Y., Tang, Z.-C., Sun, Y., Tian, J., Liu, Z.-Y., & Han, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.10091 · Cited by 65 · see citing works

Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions

Ossenkoppele, R., van der Flier, W. M., Verfaillie, S. C. J., Vrenken, H., Versteeg, A., van Schijndel, R. A., Sikkes, S. A. M., Twisk, J. W. R., Adriaanse, S. M., Zwan, M. D., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000432 · Cited by 63 · see citing works

Amyloid-β Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project

Verfaillie, S. C. J., Timmers, T., Slot, R. E. R., van der Weijden, C. W. J., Wesselman, L. M. P., Prins, N. D., Sikkes, S. A. M., Yaqub, M., Dols, A., Lammertsma, A. A., et al. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00007 · Cited by 63 · see citing works

Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI

Wolfsgruber, S., Jessen, F., Koppara, A., Kleineidam, L., Schmidtke, K., Frölich, L., Kurz, A., Schulz, S., Hampel, H. J., Heuser, I., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001399 · Cited by 63 · see citing works

Progression of Subjective Cognitive Decline to MCI or Dementia in Relation to Biomarkers for Alzheimer Disease

Rostamzadeh, A., Bohr, L., Wagner, M., Baethge, C., & Jessen, F. (2022) · Neurology · doi:10.1212/wnl.0000000000201072 · Cited by 61 · see citing works

Subjective Cognitive Impairment Is a Predominantly Benign Condition in Memory Clinic Patients Followed for 6 Years: The Gothenburg-Oslo MCI Study

Hessen, E., Eckerström, M., Nordlund, A., Almdahl, I. S., Stålhammar, J., Bjerke, M., Eckerström, C., Göthlin, M., Fladby, T., Reinvang, I., et al. (2017) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000454676 · Cited by 61 · see citing works

Gray matter network disruptions and amyloid beta in cognitively normal adults

Tijms, B. M., Kate, M. T., Wink, A. M., Visser, P. J., Ecay, M., Clerigue, M., Estanga, A., Garcia Sebastian, M., Izagirre, A., Villanua, J., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.10.015 · Cited by 59 · see citing works

Additional Use of Aβ42/Aβ40 Ratio with Cerebrospinal Fluid Biomarkers P-Tau and Aβ42 Increases the Level of Evidence of Alzheimer's Disease Pathophysiological Process in Routine Practice

Sauvée, M., Didierlaurent, G., Latarche, C., Escanyé, M., Olivier, J. L., & Malaplate, C. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131838 · Cited by 58 · see citing works

Influence of Sampling and Recruitment Methods in Studies of Subjective Cognitive Decline

Rodríguez‐Gómez, O., Ruiz, C. A., Jessen, F., Valero, S., & Boada, M. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150189 · Cited by 57 · see citing works

Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project

Verberk, I. M. W., Hendriksen, H. M. A., van Harten, A. C., Wesselman, L. M. P., Verfaillie, S. C. J., van den Bosch, K. A., Slot, R. E. R., Prins, N. D., Scheltens, P., Teunissen, C. E., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.01.007 · Cited by 57 · see citing works

Silymarin effect on amyloid-β plaque accumulation and gene expression of APP in an Alzheimer’s disease rat model

Yaghmaei, P., Azarfar, K., Dezfulian, M., & Ebrahim‐Habibi, A. (2014) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/2008-2231-22-24 · Cited by 55 · see citing works

A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline

Verfaillie, S. C. J., Slot, R. E. R., Dicks, E., Prins, N. D., Overbeek, J. M., Teunissen, C. E., Scheltens, P., Barkhof, F., van der Flier, W. M., & Tijms, B. M. (2018) · Human Brain Mapping · doi:10.1002/hbm.24065 · Cited by 50 · see citing works

Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline

Lista, S., Molinuevo, J. L., Cavedo, E., Rami, L., Amouyel, P., Teipel, S. J., Garaci, F., Toschi, N., Habert, M.-O., Blennow, K., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150202 · Cited by 53 · see citing works

High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline

Verfaillie, S. C. J., Witteman, J., Slot, R. E. R., Pruis, I. J., Vermaat, L. E. W., Prins, N. D., Schiller, N. O., van de Wiel, M. A., Scheltens, P., van Berckel, B. N. M., et al. (2019) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2019.05.006 · Cited by 51 · see citing works

Subjective Cognitive Decline, Cognitive Reserve Indicators, and the Incidence of Dementia

Jia, F., Li, Y., Li, M., & Cao, F. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2020.08.005 · Cited by 52 · see citing works

A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer’s Disease

Buckley, R. F., Villemagne, V. L., Masters, C. L., Ellis, K. A., Rowe, C. C., Johnson, K. A., Sperling, R. A., & Amariglio, R. E. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0810-z · Cited by 50 · see citing works

The ATN Framework—Moving Preclinical Alzheimer Disease to Clinical Relevance

van der Flier, W. M., & Scheltens, P. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.2967 · Cited by 49 · see citing works

Amyloid and Tau Biomarkers in Subjective Cognitive Impairment

Colijn, M. A., & Grossberg, G. T. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150180 · Cited by 48 · see citing works

Subjective Cognitive Decline and APOE ɛ4: A Systematic Review

Ali, J. I., Smart, C. M., & Gawryluk, J. R. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180248 · Cited by 46 · see citing works

Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project

Initiative, F. T. A. D. N., van Maurik, I. S., Slot, R. E. R., Verfaillie, S. C. J., Zwan, M. D., Bouwman, F. H., Prins, N. D., Teunissen, C. E., Scheltens, P., Barkhof, F., et al. (2019) · Alzheimer's Research &amp; Therapy · doi:10.1186/s13195-019-0487-y · Cited by 47 · see citing works

Soluble Amyloid-β Consumption in Alzheimer’s Disease

Espay, A. J., Sturchio, A., Schneider, L. S., & Ezzat, K. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210415 · Cited by 46 · see citing works

Reduced future‐oriented decision making in individuals with subjective cognitive decline: A functional MRI study

Hu, X., Uhle, F., Fließbach, K., Wagner, M., Han, Y., Weber, B., & Jessen, F. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.02.005 · Cited by 43 · see citing works

Five‐year biomarker progression variability for Alzheimer's disease dementia prediction: Can a complex instrumental activities of daily living marker fill in the gaps?

Tarnanas, I., Tsolaki, A., Wiederhold, M. D., Wiederhold, B. K., & Tsolaki, M. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.10.005 · Cited by 43 · see citing works

Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease—Data from three memory clinic studies

Hu, X., Teunissen, C. E., Spottke, A. E., Heneka, M. T., Düzel, E., Peters, O., Li, S., Priller, J., Büerger, K., Teipel, S. J., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.09.002 · Cited by 42 · see citing works

Subjective Cognitive Decline and Alzheimer's Disease Spectrum Disorder

Hong, Y. J., & Lee, J. (2017) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2017.16.2.40 · Cited by 41 · see citing works

Accelerated long-term forgetting in healthy older adults predicts cognitive decline over 1 year

Wearn, A. R., Saunders-Jennings, E., Nurdal, V., Hadley, E., Knight, M. J., Newson, M., Kauppinen, R. A., & Coulthard, E. J. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00693-4 · Cited by 40 · see citing works

Comparison of odor identification among amnestic and non-amnestic mild cognitive impairment, subjective cognitive decline, and early Alzheimer’s dementia

Park, S. J., Lee, J., Lee, K., & Kim, J. (2018) · Neurological Sciences · doi:10.1007/s10072-018-3261-1 · Cited by 39 · see citing works

Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid β1‐42 in Alzheimer's Disease Neuroimaging Initiative participants

Li, W., Risacher, S. L., Gao, S., Boehm, S. L., Elmendorf, J. S., Saykin, A. J., & Initiative, A. D. N. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.11.002 · Cited by 39 · see citing works

Jiao-tai-wan inhibits inflammation of the gut-brain-axis and attenuates cognitive impairment in insomnic rats

Su, H., Zhang, C., Zou, X. G., Lu, F., Zeng, Y., Guan, H., Ren, Y., Yuan, F., Xu, L., Zhang, M., et al. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112478 · Cited by 38 · see citing works

Lifestyle Factors Are Important Contributors to Subjective Memory Complaints among Patients without Objective Memory Impairment or Positive Neurochemical Biomarkers for Alzheimer’s Disease

Miley-Åkerstedt, A., Jelić, V., Marklund, K., Walles, H., Åkerstedt, T., Hagman, G., & Andersson, C. (2018) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000493749 · Cited by 35 · see citing works

Relationship of cognitive strategy use to prospective memory performance in a diverse sample of nondemented older adults with varying degrees of cognitive complaints and impairment

Aronov, A., Rabin, L. A., Fogel, J., Chi, S. Y., Kann, S. J., Abdelhak, N., & Zimmerman, M. E. (2014) · Aging Neuropsychology and Cognition · doi:10.1080/13825585.2014.984653 · Cited by 37 · see citing works

Novel Therapeutic Strategies in Alzheimer’s Disease: Pitfalls and Challenges of Anti-Amyloid Therapies and Beyond

Tondo, G., Marchi, F. D., Bonardi, F., Menegon, F., Verrini, G., Aprile, D., Anselmi, M., Mazzini, L., & Comi, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113098 · Cited by 43 · see citing works

Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume

Caldwell, J., Cummings, J. L., Banks, S. J., Palmqvist, S., & Hansson, O. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0565-1 · Cited by 37 · see citing works

Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers—results from the DELCODE study

Sannemann, L., Schild, A., Altenstein, S., Bartels, C., Brosseron, F., Büerger, K., Cosma, N. C., Fließbach, K., Freiesleben, S. D., Glanz, W., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00701-7 · Cited by 36 · see citing works

SELF-REPORTED MEMORY COMPLAINTS: A COMPARISON OF DEMENTED AND UNIMPAIRED OUTCOMES

Kryscio, R. J., Abner, E. L., Jicha, G. A., Nelson, P. T., Smith, C. D., Eldik, L. J. V., Lou, W., Fardo, D. W., Cooper, G. E., & Schmitt, F. A. (2015) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2015.74 · Cited by 34 · see citing works

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease

Mofrad, R. B., Schoonenboom, N. S. M., Tijms, B. M., Scheltens, P., Visser, P. J., van der Flier, W. M., & Teunissen, C. E. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.10.004 · Cited by 33 · see citing works

Impact of a clinical decision support tool on prediction of progression in early-stage dementia: a prospective validation study

Bruun, M., Frederiksen, K. S., Rhodius‐Meester, H. F. M., Baroni, M., Gjerum, L., Koikkalainen, J. R., Urhemaa, T., Tolonen, A. J., van Gils, M., Rueckert, D., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0482-3 · Cited by 31 · see citing works

Change of Amyloid-β 1-42 Toxic Conformer Ratio After Cerebrospinal Fluid Diversion Predicts Long-Term Cognitive Outcome in Patients with Idiopathic Normal Pressure Hydrocephalus

Akiba, C., Nakajima, M., Miyajima, M., Ogino, I., Motoi, Y., Kawamura, K., Adachi, S., Kondo, A., Sugano, H., Tokuda, T., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180059 · Cited by 30 · see citing works

Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics

Ritter, A. R., & Cummings, J. L. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00186 · Cited by 29 · see citing works

Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia

van Wijk, N., Slot, R. E. R., Duits, F. H., Strik, M., Biesheuvel, E., Sijben, J., Blankenstein, M. A., Bierau, J., van der Flier, W. M., Scheltens, P., et al. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.04.005 · Cited by 29 · see citing works

In Situ Monitoring the Aggregation Dynamics of Amyloid-β Protein Aβ42 in Physiological Media via a Raman-Based Frequency Shift Method

Zhu, W., Wang, Y., Xie, D., Cheng, L., Wang, P., Zeng, Q., Li, M., & Zhao, Y. (2018) · ACS Applied Bio Materials · doi:10.1021/acsabm.8b00257 · Cited by 28 · see citing works

Biomarker-based signature of alzheimer's disease in pre-MCI individuals

Chipi, E., Salvadori, N., Farotti, L., & Parnetti, L. (2019) · Brain Sciences · doi:10.3390/brainsci9090213 · Cited by 27 · see citing works

Cerebrospinal fluid biomarkers for neuropsychological symptoms in early stage of late-onset Alzheimer's disease

Kuo, H., Yen, H., Huang, C., Hsu, W., Wei, H.-J., & Lin, C. (2014) · International Journal of Neuroscience · doi:10.3109/00207454.2014.971787 · Cited by 27 · see citing works

Cerebral Amyloid Angiopathy, Alzheimer’s Disease and MicroRNA: miRNA as Diagnostic Biomarkers and Potential Therapeutic Targets

Furr, J. W., Morales‐Scheihing, D., Manwani, B., Lee, J., & McCullough, L. D. (2019) · NeuroMolecular Medicine · doi:10.1007/s12017-019-08568-0 · Cited by 28 · see citing works

Connected Speech Deficit as an Early Hallmark of CSF-defined Alzheimer’s Disease and Correlation with Cerebral Hypoperfusion Pattern

Mazzon, G., Ajčević, M., Cattaruzza, T., Menichelli, A., Guerriero, M., Capitanio, S., Pesavento, V., Dore, F., Sorbi, S., Manganotti, P., et al. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190506141733 · Cited by 26 · see citing works

Featured Article Cerebrospinal fluid Ab42 is the best predictor of clinical progression in patients with subjective complaints

van Harten, A. C., Visser, P. J., Pijnenburg, Y. A. L., Teunissen, C. E., Blankenstein, M. A., Scheltens, P., & van der Flier, W. M. (2013) · Cited by 5 · see citing works

O1‐04‐04: CSF biomarkers predict progression in patients with subjective memory complaints

van Harten, A. C., Visser, P. J., Scheltens, P., van der Flier, W. M., Pijnenburg, Y. A. L., & Blankenstein, M. A. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.251

Usefulness of CSF Biomarkers in Predicting the Progression of Amnesic and Nonamnesic Mild Cognitive Impairment to Alzheimer’s Disease

Ortega, R. L., Dakterzada, F., Arias, A. M., Blasco, E., Naudí, A., Purroy, F. F., & Piñol‐Ripoll, G. (2019) · Current Aging Science · doi:10.2174/1874609812666190112095430 · Cited by 20 · see citing works

Biomarkers of Alzheimer’s Disease and Cerebrovascular Lesions and Clinical Progression in Patients with Subjective Cognitive Decline: A Systematic Review

Scarth, M., Rissanen, I. L., Scholten, R. J. P. M., & Geerlings, M. I. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210218 · Cited by 18 · see citing works

Cerebrospinal Fluid Tau and β-Amyloid 42 Proteins Identify Alzheimer Disease in Subjects With Mild Cognitive Impairment

Riemenschneider, M. J., Lautenschlager, N. T., Wagenpfeil, S., Diehl, J., Drzezga, A. E., & Kurz, A. (2002) · Archives of Neurology · doi:10.1001/archneur.59.11.1729 · Cited by 212 · see citing works